Current pharmacotherapy for treating pediatric nonalcoholic fatty liver disease

Research output: Contribution to journalArticlepeer-review


Introduction: In the past decade, nonalcoholic fatty liver disease (NAFLD) had rapidly become one of the most common liver diseases. If efficient therapeutic strategies will not reduce the prevalence of NAFLD in children soon, serious deleterious effects on the quality of life of these patients in adulthood are expected. Lifestyle modification is the current first-line therapy for pediatric NAFLD, even though it is difficult to obtain and to maintain. Therefore, lifestyle changes are usually ineffective and long-lasting improvement of the NAFLD-associated liver damage is rarely observed. As guidelines for the management of NAFLD in children are still lacking, the identification of effective treatments represents a challenge for pediatric hepatologists in the near future. Areas covered: Here, we review the existing therapeutic approaches for treating NAFLD in children and overview all ongoing clinical trials for new promising drugs in pediatric setting. Expert opinion: Considering the multifactorial pathogenesis and the wide spectrum of histological and clinical features of NAFLD, we believe that a drug mix, containing agents that are effective against the principal pathogenetic factors, associated with lifestyle modification, could represent the winning choice of treatment for pediatric NAFLD.

Original languageEnglish
Pages (from-to)2501-2511
Number of pages11
JournalExpert Opinion on Pharmacotherapy
Issue number17
Publication statusPublished - Dec 1 2014


  • Children
  • Nonalcoholic fatty liver disease
  • Nonalcoholic steatohepatitis
  • Obesity
  • Treatment

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Medicine(all)


Dive into the research topics of 'Current pharmacotherapy for treating pediatric nonalcoholic fatty liver disease'. Together they form a unique fingerprint.

Cite this